Abstract: Regorafenib (BAY 73-4506) is an oral multi-kinase inhibitor that has demonstrated significant clinical efficacy in treating various malignancies, including colorectal cancer (CRC), hepatocellular carcinoma (HCC), and gastrointestinal stromal tumors (GIST). Beyond its direct anti-angiogenic and anti-proliferative effects on tumor cells, emerging research highlights its profound ability to reprogram the tumor microenvironment (TME). By modulating immune cell populations—such as tumor-associated macrophages (TAMs), regulatory T cells (Tregs), and natural killer (NK) cells—and normalizing tumor vasculature, regorafenib transforms the immunosuppressive TME into an immunostimulatory niche. This review explores the pharmacological activity, molecular mechanisms, and structure-activity relationship of regorafenib, with a specific focus on its synergistic potential when combined with immune checkpoint inhibitors (ICIs). Current limitations and future perspectives are also discussed to guide precision oncology strategies and overcome resistance to immunotherapy.
1. Introduction
Regorafenib (BAY 73-4506) is a potent, oral multi-kinase inhibitor approved for the treatment of metastatic colorectal cancer (mCRC), advanced gastrointestinal stromal tumors (GIST), and hepatocellular carcinoma (HCC) [1][3]. While traditional targeted therapies primarily focus on direct tumor cell killing, the therapeutic landscape has shifted towards understanding and manipulating the tumor microenvironment (TME). The TME comprises immune cells, fibroblasts, endothelial cells, and extracellular matrix components that collectively foster an immunosuppressive niche. This environment facilitates tumor evasion and contributes to primary or acquired resistance to immune checkpoint inhibitors (ICIs), such as anti-PD-1/PD-L1 therapies [1][5]. Regorafenib has emerged as a critical agent capable of reprogramming this hostile TME, thereby enhancing anti-tumor immunity and overcoming resistance to immunotherapy [1].
2. Pharmacological Activity
Regorafenib exhibits broad-spectrum pharmacological activity by targeting oncogenic, angiogenic, and stromal receptor tyrosine kinases [3][6]. Clinically, it has shown efficacy across a wide range of solid tumors, including mCRC, GIST, HCC, biliary tract adenocarcinoma, soft-tissue sarcomas, osteosarcoma, and recurrent glioblastoma [3][16]. In mCRC, the CORRECT and CONCUR phase III trials demonstrated significant improvements in overall survival (OS) and progression-free survival (PFS) [3]. In GIST, it is highly effective against tumors refractory to prior lines of therapy like imatinib and sunitinib [12][14]. Furthermore, regorafenib is utilized as a standard second-line systemic treatment for HCC [7]. Its pharmacological profile is unique because it not only halts tumor progression but also actively modulates the immune landscape, making it a prime candidate for combination with ICIs [1][5].
3. Molecular Mechanism of Action
The mechanism of action of regorafenib in TME reprogramming is multifaceted, involving vascular normalization, immune cell modulation, and the alteration of tumor immunogenicity.
Angiogenesis and Vascular Normalization: Regorafenib inhibits key angiogenic receptors, including VEGFR1-3, TIE2, PDGFR, and FGFR [1][16]. By targeting VEGFR2 and TIE2, it reduces abnormal tumor angiogenesis. Importantly, at optimal intermediate doses, it promotes the "normalization" of tumor vasculature, which improves tissue perfusion and alleviates hypoxia [1]. Hypoxia typically drives the recruitment of immunosuppressive cells like myeloid-derived suppressor cells (MDSCs) and Tregs, and upregulates PD-L1; thus, alleviating hypoxia directly counteracts these immune-evasive mechanisms [1][5].
Modulation of Immune Cells: Regorafenib exerts profound effects on various immune cell populations within the TME. It inhibits the TIE2 and CSF1R pathways, reducing the infiltration of M2-like tumor-associated macrophages (TAMs) and promoting their repolarization toward the anti-tumor M1 phenotype [1][2]. It also inhibits the p38MAPK/Creb1/Klf4 pathway to enhance macrophage-mediated immunity [1]. For T cells, the drug increases the infiltration and activation of CD8+ T cells by inducing CXCL10 expression, while significantly reducing the accumulation of immunosuppressive Tregs and MDSCs [1][5]. Furthermore, regorafenib enhances Natural Killer (NK) cell function by suppressing the transcription of ADAM10 and ADAM9, which prevents the proteolytic shedding of MICA (a ligand for the NKG2D receptor on NK cells) [1]. It also inhibits STAT3, limiting the expression of the immunosuppressive molecule CD24 [1][9]. Additionally, regorafenib suppresses the proliferation and promotes the apoptosis of cancer-associated fibroblasts (CAFs) via the AKT/Bcl-2/Bax pathway, dismantling the supportive stromal network of the tumor [1].
Tumor Immunogenicity: Regorafenib uniquely downregulates IFN-γ-induced PD-L1 and IDO1 expression on tumor cells by inhibiting RET/Src signaling [1]. Simultaneously, it upregulates MHC-I expression via the IFN-γ/STAT1 pathway, enhancing the recognition of tumor cells by the immune system [1].
4. Structure-Activity Relationship (SAR)
Regorafenib is structurally closely related to sorafenib, an earlier generation multi-kinase inhibitor. The critical structural difference is the addition of a fluorine atom to the central phenyl ring of the sorafenib molecule [1]. This specific halogenation enhances its pharmacological activity and biochemical potency against a broader range of angiogenic and oncogenic kinases compared to its predecessor. This structural modification allows for more robust modulation of the TME and greater overall anti-tumor efficacy [1].
5. Current Limitations
Despite its efficacy, regorafenib therapy faces several clinical limitations. Toxicity and adverse events (AEs) are significant hurdles; common AEs include hand-foot skin reaction (HFSR), fatigue, hypertension, and diarrhea [3][14]. These toxicities often necessitate dose modifications or interruptions, which can compromise therapeutic efficacy. Furthermore, primary and acquired resistance mechanisms limit long-term success [11]. The heterogeneity of tumors means that not all patients respond to TME reprogramming, and there is currently a lack of highly sensitive and specific predictive biomarkers to identify which patients will benefit most from regorafenib, either as a monotherapy or in combination regimens [1].
6. Future Perspectives
The future of regorafenib lies in its integration with immunotherapy. Clinical trials (e.g., REGONIVO) combining regorafenib with anti-PD-1/PD-L1 agents (such as nivolumab, pembrolizumab, and avelumab) have shown synergistic anti-tumor efficacy and manageable safety profiles in CRC, HCC, and gastric cancers [1][2][5]. Future research must focus on optimizing dosing schedules (e.g., intermediate dosing to achieve vascular normalization without inducing severe hypoxia) to maximize immune infiltration [1]. Additionally, the identification of robust biomarkers—such as ANG-1, MIR122, or specific gene signatures (e.g., HIF1A, CDKN1A)—will be crucial for patient stratification and the realization of precision oncology [1].
